NVTA - Invitae Corporation

NYSE - NYSE Delayed Price. Currency in USD
17.39
+0.01 (+0.06%)
At close: 4:03PM EST
Stock chart is not supported by your current browser
Previous Close17.38
Open17.38
Bid0.00 x 1300
Ask0.00 x 800
Day's Range17.01 - 17.69
52 Week Range9.04 - 28.75
Volume970,360
Avg. Volume2,114,784
Market Cap1.692B
Beta (3Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Invitae to Acquire Clear Genetics
    PR Newswire

    Invitae to Acquire Clear Genetics

    SAN FRANCISCO, Nov. 11, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Clear Genetics, a leading developer of software for providing genetic services at scale. Using intuitive chatbots, Clear Genetics equips patients with actionable information throughout the genetic testing process and provides guidance for understanding test results. The acquisition will further expand Invitae's ability to scale and deliver genetic information as a part of routine medical care.

  • PR Newswire

    University of Vermont Health Network begins offering Genomic DNA Testing

    BURLINGTON, Vt., Nov. 8, 2019 /PRNewswire/ -- The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks into routine medical care, which holds promise for providing Vermonters with valuable information to guide their health decisions. "Our overall health and longevity are determined about 30 percent by genetics," said Debra Leonard, MD, PhD, Chair, Pathology and Laboratory Medicine.

  • Invitae Reports $56.5 Million in Quarterly Revenue Driven by 129,000 Samples
    PR Newswire

    Invitae Reports $56.5 Million in Quarterly Revenue Driven by 129,000 Samples

    -- Increased quarterly revenue by 51% and volume by 65% year-over-year -- -- Now in network with Cigna, all major payers with approximately 295 million covered lives -- -- Hosting conference call and webcast ...

  • Invitae Highlights Importance of Medical Genetics, Honors Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 38th Annual Conference
    PR Newswire

    Invitae Highlights Importance of Medical Genetics, Honors Excellence in Genetic Counseling at National Society of Genetic Counselors (NSGC) 38th Annual Conference

    SALT LAKE CITY , Nov. 5, 2019 /PRNewswire/ -- Researchers from   Invitae Corporation (NYSE: NVTA), a leading medical genetics company, are presenting research this week at the National Society of Genetic ...

  • Invitae to announce third quarter 2019 financial results on November 6, 2019
    PR Newswire

    Invitae to announce third quarter 2019 financial results on November 6, 2019

    SAN FRANCISCO, Oct. 23, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 9085356.

  • Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward
    PR Newswire

    Research presented by Invitae at the American Society of Human Genetics Meeting Pushes Science and Practice of Genetics Forward

    -- Advances in classification, new approaches to genetics in cancer and implications of primary and secondary findings for clinical care among wide-ranging data presentations -- HOUSTON , Oct. 17, 2019 ...

  • Invitae Expands Detect Program to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
    PR Newswire

    Invitae Expands Detect Program to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients

    SAN FRANCISCO, Sept. 9, 2019 /PRNewswire/ -- Invitae (NVTA), a leading medical genetics company, today announced the availability of Detect Hereditary Pancreatic Cancer, a testing program that offers no-charge genetic testing and counseling to patients with pancreatic cancer. Genetic testing is recommended by clinicians for all pancreatic cancer patients to guide treatment choices and evaluate eligibility for clinical trials.

  • Invitae Prices Upsized Offering of $300 Million of Convertible Senior Notes
    PR Newswire

    Invitae Prices Upsized Offering of $300 Million of Convertible Senior Notes

    SAN FRANCISCO, Sept. 6, 2019 /PRNewswire/ -- Invitae Corporation (NVTA) announced the pricing on September 5, 2019 of $300.0 million aggregate principal amount of 2.00% convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The aggregate principal amount of the offering was increased from the previously announced offering size of $200.0 million. Invitae granted the initial purchasers of the notes a 13-day option to purchase up to an additional $50.0 million principal amount of notes on the same terms and conditions.

  • Invitae Announces Proposed Offering of $200 Million of Convertible Senior Notes
    PR Newswire

    Invitae Announces Proposed Offering of $200 Million of Convertible Senior Notes

    SAN FRANCISCO, Sept. 4, 2019 /PRNewswire/ -- Invitae Corporation (NVTA) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In connection with the offering, Invitae expects to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $30.0 million principal amount of notes on the same terms and conditions. Invitae intends to use the net proceeds from the offering of the notes to repay, including a prepayment premium, the $75.0 million in aggregate principal amount of notes outstanding under its 2018 Note Purchase Agreement and for international expansion, infrastructure investment, working capital and other general corporate purposes.

  • GlobeNewswire

    Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients

    SMA Identified program offers genetic testing for SMA at no charge to individuals in the U.S. CAMBRIDGE, Mass. and SAN FRANCISCO, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (BIIB) and Invitae Corporation (NVTA) today announced that SMA STAT, a new, rapid-turnaround genetic test for spinal muscular atrophy (SMA), will be offered at no charge to individuals in the U.S. as part of the SMA Identified program. The SMA STAT test reduces the time needed for genetic testing to help confirm a definitive diagnosis of SMA from 21 to four days, enabling individuals and physicians to plan and begin treatment earlier for what is often a life-threatening disease.

  • Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume
    PR Newswire

    Invitae Reports $53.5 Million in Quarterly Revenue Driven by More Than 111,000 Samples in Quarterly Volume

    -- Increased quarterly revenue by 43% and volume by 52% year-over-year -- -- Announced appointment of Sean George as chairman of the Board of Directors, retirement of Randy Scott as executive chairman, ...

  • Invitae Launches Detect Programs to Make it Easier for Patients to Get Genetic Testing for Prostate Cancer, Muscular Dystrophy and Heart Conditions
    PR Newswire

    Invitae Launches Detect Programs to Make it Easier for Patients to Get Genetic Testing for Prostate Cancer, Muscular Dystrophy and Heart Conditions

    SAN FRANCISCO, July 24, 2019 /PRNewswire/ -- Invitae (NVTA), a leading medical genetics company, today announced the availability of its Detect programs to provide no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. Research has shown no-charge testing programs result in earlier diagnosis and treatment. Enrollment is now open for Detect programs in four conditions: muscular dystrophy, prostate cancer, cardiomyopathy and arrhythmia and lysosomal storage diseases.

  • Invitae to announce second quarter 2019 financial results on August 6, 2019
    PR Newswire

    Invitae to announce second quarter 2019 financial results on August 6, 2019

    SAN FRANCISCO, July 23, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced that it will report its second quarter 2019 financial results on Tuesday, August 6, 2019 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 6153749.

  • Invitae to Acquire Jungla to Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis to Deliver Deeper, More Informative Results to Patients
    PR Newswire

    Invitae to Acquire Jungla to Advance Genetic Variant Interpretation, Adds Supplemental RNA Analysis to Deliver Deeper, More Informative Results to Patients

    SAN FRANCISCO, July 11, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Jungla Inc., a privately held company funded by Andreessen Horowitz (a16z) that has developed a cloud-based platform that combines clinical knowledge with advances in functional genomics, biophysics, cellular engineering, machine learning, and distributed systems to help clinicians and patients understand the results of genetic and genomic tests. The combination is expected to further enhance Invitae's genetic variant interpretation and ability to deliver high-quality, more affordable genetic testing for use in mainstream medical care.

  • GlobeNewswire

    Capital Market Laboratories (CMLviz) Interviews Invitae’s CEO –Invitae’s Non-Invasive Prenatal Screening Tests Can be a 50% Gross Margin Business

    LOS ANGELES, June 27, 2019 -- In an interview with Capital Market Laboratories (CMLviz), chief executive officer of Invitae (NYSE:NVTA) Sean George had a clear message: Invitae.

  • Invitae Reports Inducement Grants Under NYSE Rule 303A.08 to Former Employees of Singular Bio, Inc. in Connection with Closing of Acquisition
    PR Newswire

    Invitae Reports Inducement Grants Under NYSE Rule 303A.08 to Former Employees of Singular Bio, Inc. in Connection with Closing of Acquisition

    SAN FRANCISCO, June 20, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced that it granted time-based and development milestone-based restricted stock units ("RSUs") to new employees who joined Invitae in connection with its acquisition of Singular Bio, Inc. The RSUs were granted under Invitae's 2015 Stock Incentive Plan, which was amended and restated to create an additional pool of shares of Invitae common stock to be used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08"). The RSUs were approved by the Board of Directors of Invitae and were made as an inducement material to each employee entering into employment with Invitae in reliance on the employment inducement exemption under Rule 303A.08.

  • Invitae to Acquire Singular Bio to Help Increase Access to Genetic Screening in Early Pregnancy
    PR Newswire

    Invitae to Acquire Singular Bio to Help Increase Access to Genetic Screening in Early Pregnancy

    SAN FRANCISCO, June 17, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Singular Bio, Inc., a privately held company developing single molecule detection technology that enables lower costs and expanded use of high-quality, cell-free, nucleic acid analysis, initially for application in non-invasive prenatal screening (NIPS). "Since we began, Invitae has invested deeply to harness the power of the most advanced genetic testing technologies in order to deliver expert-level genetic information at scale, and bringing this company into Invitae is the next step in that process," said Sean George, PhD, co-founder and chief executive officer of Invitae.

  • X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
    Business Wire

    X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease

    X4 Pharmaceuticals, Inc. (XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, and Invitae Corporation (NVTA), a leader in medical genetics, today announced a partnership to provide genetic testing at no cost to patients through its collaborative PATH4WARD program. This initiative provides greater access to faster and earlier diagnosis for individuals who may carry a genetic mutation known to be associated with WHIM syndrome and Severe Congenital Neutropenia (SCN) – a group of rare inherited primary immunodeficiencies (PIs).

  • Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disorders
    PR Newswire

    Invitae Announces ID YOUR IRD Program to Expand Access to Genetic Testing for Inherited Retinal Disorders

    SAN FRANCISCO, June 12, 2019 /PRNewswire/ -- Invitae (NVTA), a leading medical genetics company, today announced the launch of ID YOUR IRD, an initiative with Spark Therapeutics to offer genetic testing at no charge to patients suspected by their healthcare providers of having an inherited retinal disease (IRD), a group of rare, progressive eye disorders that may result in vision loss or blindness and are caused by inherited genetic changes.

  • Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trust
    PR Newswire

    Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trust

    SAN FRANCISCO, June 3, 2019 /PRNewswire/ -- Invitae (NVTA), a leader in medical genetics, today announced the availability of its new service for consumers, which makes it easier for consumers to order and receive the same high-quality, medical genetic testing from Invitae that experts use and trust. The service provides affordable testing along with guidance from a network of trained clinicians to help consumers get health information they can act on.

  • Research from Invitae Demonstrates the Importance of Germline Multigene Panel Testing in Guiding Therapy for Expanding Groups of Cancer Patients
    PR Newswire

    Research from Invitae Demonstrates the Importance of Germline Multigene Panel Testing in Guiding Therapy for Expanding Groups of Cancer Patients

    - Data to be presented at the American Society of Clinical Oncology Annual Meeting - - Underscores importance of genetic testing to guide precision medicine treatment and improve family screening - SAN ...

  • Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program
    Business Wire

    Horizon Therapeutics plc and Invitae Corporation Launch Urea Cycle Disorder Genetic Testing Program

    Horizon Therapeutics plc (HZNP) in partnership with Invitae Corporation (NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed to speed diagnosis and enable physicians to offer genetic testing at no-charge to people who may have a UCD, including their family members. Horizon’s support of the UCD Genetic Testing Program facilitates the genetic tests and services offered and performed by Invitae.

  • Invitae to Present at the 2019 William Blair Growth Stock Conference
    PR Newswire

    Invitae to Present at the 2019 William Blair Growth Stock Conference

    SAN FRANCISCO, May 22, 2019 /PRNewswire/ -- Invitae Corporation (NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae will present at the 2019 William Blair Growth Stock Conference on Wednesday, June 5, 2019 at 2:40 p.m. Central / 12:40 p.m. Pacific in Chicago. Invitae Corporation (NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people.

  • Invitae to Present at the UBS Global Healthcare Conference
    PR Newswire

    Invitae to Present at the UBS Global Healthcare Conference

    SAN FRANCISCO , May 15, 2019 /PRNewswire/ --  Invitae Corporation  (NYSE: NVTA), the leader in advanced medical genetics, today announced that Sean George , co-founder and chief executive officer of Invitae, ...

  • Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year
    PR Newswire

    Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year

    -- On track to deliver more than 500,000 test samples and more than $220 million in revenue in 2019 -- -- Signed eight new biopharma partnerships in the quarter, expanding the breadth of the genome network ...